New COVID-19 vaccine from Novavax available from December!

New COVID-19 vaccine from Novavax available from December!

The new Novavax Covid 19 vaccine, which is specially tailored to the JN.1 variant, received approval in the European Union on October 8, 2024. This was made possible by a positive statement by the committee for human medicinal products from the European Medicines Agency (EMA). Nevertheless, a spokesman for a ministry stated that the final approval of the vaccination characters by the registration authority could not take place until the end of November. The vaccine is expected to be available free of charge in medical practices and public vaccination facilities in mid-December, according to the message of noen.at .

The updated vaccine Nuvaxovid ™ 2024-2025 (NVX-COV2705) is aimed at people aged 12 and over to prevent covid-19. The approval is based on non-clinical data that prove a cross reactivity against the JN.1 variant and related viruses. Novavax uses its innovative Matrix-M ™ adjuvans technology, which strengthens and widened the immune response, such as Novavax The most common side effects observed in clinical studies include headaches, nausea and tiredness.

vaccine hardly suitable for everyone

The approval granted as part of the emergency permit in the United States also applies to the European market. Nevertheless, people with known severe allergies or a weakened immune system should be careful. The release of the vaccine is supported by various security and effectiveness studies, but it is pointed out that the vaccine may not protect against all virus variants.